Medical Professionals Reference (MPR)FDA Approves Novel Hot Flash Therapy Lynkuet

The FDA approval of Lynkuet® (elinzanetant) introduces a novel dual NK-1,3 receptor antagonist for moderate to severe vasomotor symptoms (VMS) in menopause. Based on two Phase 3 trials (OASIS 1 and 2) enrolling 796 women with ≥50 moderate to severe hot flashes weekly, elinzanetant 120mg daily demonstrated statistically significant reductions in both frequency (≥2 hot flashes/24 hours) and severity versus placebo at weeks 4 and 12. This non-hormonal mechanism targeting KNDy neurons in the hypothalamus offers an alternative to hormone therapy for patients with contraindications or preferences against estrogen-based treatment.

🔬 Key Clinical Considerations

• Efficacy magnitude: Elinzanetant reduced moderate to severe VMS frequency by 3.04-3.29 episodes/24 hours at week 4 and 3.22-3.24 episodes at week 12 versus placebo (all P <.0001), with consistent severity reductions across both pivotal trials.
• Mechanism distinction: Dual NK-1,3 receptor antagonism modulates hypothalamic KNDy neurons without estrogenic effects, providing a non-hormonal option distinct from existing therapies like fezolinetant (NK-3 only) or hormone replacement therapy.
• Safety profile requires monitoring: Most common adverse events include headache, fatigue, dizziness, and somnolence; hepatic transaminase elevations mandate baseline liver function testing before initiation and periodic monitoring during treatment.
• Absolute contraindications: Pregnancy (risk of pregnancy loss/stillbirth) represents an absolute contraindication; use caution in patients with seizure history, and dosage modifications required with certain concomitant medications affecting drug metabolism.
• Clinical trial population: Study participants (mean age 54.5 years) had significant baseline symptom burden (≥50 moderate to severe hot flashes/week); real-world effectiveness in patients with lower symptom frequency remains to be established.

💊 Clinical Practice Impact

• Patient Selection & Counseling: Identify appropriate candidates with moderate to severe VMS (≥50 episodes weekly or significant quality-of-life impact) who have contraindications to hormone therapy, prefer non-hormonal options, or failed previous treatments. Counsel patients on expected timeline for symptom improvement (statistically significant benefit by week 4) and common side effects including headache and fatigue.
• Pre-Treatment Assessment: Obtain baseline hepatic function panel (AST, ALT, bilirubin) before initiating therapy; confirm negative pregnancy status in women of reproductive potential given absolute contraindication. Review medication list for drug interactions requiring dosage adjustment and assess seizure history for heightened monitoring needs.
• Dosing & Administration: Prescribe 120mg (two 60mg capsules) orally once daily at bedtime at consistent times to optimize adherence and potentially minimize daytime somnolence/dizziness. Emphasize importance of daily dosing consistency and review specific concomitant medication interactions that necessitate dose modifications.
• Monitoring Strategy: Schedule follow-up at 4-6 weeks to assess efficacy using patient-reported outcomes and tolerability; repeat liver function testing periodically based on clinical judgment and package insert recommendations. Consider dose discontinuation or adjustment if hepatic transaminase elevations occur or side effects prove intolerable.
• Alternative Therapy Positioning: Position elinzanetant as a non-hormonal alternative alongside fezolinetant, selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), or gabapentin for patients unsuitable for hormone therapy, while maintaining hormone replacement as first-line for appropriate candidates without contraindications.

More on Vasomotor Symptoms